Filing Details

Accession Number:
0001764013-24-000097
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-05-24 16:14:44
Reporting Period:
2024-05-22
Accepted Time:
2024-05-24 16:14:44
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1764013 Immunovant Inc. IMVT Biological Products, (No Disgnostic Substances) (2836) 832771572
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1796290 G. Julia Butchko C/O Immunovant, Inc.
320 W 37Th Street, 6Th Floor
New York NY 10018
Chief Development Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-05-22 3,247 $29.65 448,380 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on May 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.31 - $30.02 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.